Correlation Between Molecular Partners and EPIRUS Biopharmaceutica
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and EPIRUS Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and EPIRUS Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and EPIRUS Biopharmaceuticals, you can compare the effects of market volatilities on Molecular Partners and EPIRUS Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of EPIRUS Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and EPIRUS Biopharmaceutica.
Diversification Opportunities for Molecular Partners and EPIRUS Biopharmaceutica
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Molecular and EPIRUS is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and EPIRUS Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on EPIRUS Biopharmaceuticals and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with EPIRUS Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of EPIRUS Biopharmaceuticals has no effect on the direction of Molecular Partners i.e., Molecular Partners and EPIRUS Biopharmaceutica go up and down completely randomly.
Pair Corralation between Molecular Partners and EPIRUS Biopharmaceutica
If you would invest 0.01 in EPIRUS Biopharmaceuticals on September 2, 2024 and sell it today you would earn a total of 0.00 from holding EPIRUS Biopharmaceuticals or generate 0.0% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 4.76% |
| Values | Daily Returns |
Molecular Partners AG vs. EPIRUS Biopharmaceuticals
Performance |
| Timeline |
| Molecular Partners |
| EPIRUS Biopharmaceuticals |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Molecular Partners and EPIRUS Biopharmaceutica Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and EPIRUS Biopharmaceutica
The main advantage of trading using opposite Molecular Partners and EPIRUS Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, EPIRUS Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will offset losses from the drop in EPIRUS Biopharmaceutica's long position.| Molecular Partners vs. Tff Pharmaceuticals | Molecular Partners vs. Eliem Therapeutics | Molecular Partners vs. Inhibrx | Molecular Partners vs. Enliven Therapeutics |
| EPIRUS Biopharmaceutica vs. NovAccess Global | EPIRUS Biopharmaceutica vs. Vg Life Sciences | EPIRUS Biopharmaceutica vs. Genenta Science SpA | EPIRUS Biopharmaceutica vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |